Heart failure affects ~6.7 million U.S. adults and is projected to reach 8.7 million by 2030, with prevalence rising from 1.95% at ages 40 to 59 to 12.6% among those 80 and older. The largest avoidable treatment gap is delayed initiation, incomplete use, and slow optimization. In HFrEF, low doses of all four classes should be started early, then individualized to blood pressure, kidney function, potassium, congestion, comorbidities, and affordability. SGLT2 inhibitors reduce heart failure events across the ejection-fraction spectrum, with or without diabetes. Diuretics relieve congestion but do not replace disease-modifying therapy; modest creatinine increases or low blood pressure should prompt reassessment before treatment withdrawal.
AAVBC's Heart Failure Medication Treatment Utilization Quick Reference Guide equips PCPs and care teams with an evidence-aligned reference for rapid four-pillar HFrEF therapy, appropriate early SGLT2 inhibitor use in HFmrEF and HFpEF, titration and monitoring, avoidance of medications that worsen heart failure, and continuation of therapy when ejection fraction improves. It also provides cost-smart prescribing strategies, generic and formulary alternatives, and closed-loop post-discharge pathways that verify access, labs, fills, and early follow-up. By integrating tolerability, affordability, and continuity of care, the guide helps sustain guideline-directed therapy and improve outcomes for older adults.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of heart failure medication treatment — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
Heart failure affects ~6.7 million U.S. adults and is projected to reach 8.7 million by 2030, with prevalence rising from 1.95% at ages 40 to 59 to 12.6% among those 80 and older. The largest avoidable treatment gap is delayed initiation, incomplete use, and slow optimization. In HFrEF, low doses of all four classes should be started early, then individualized to blood pressure, kidney function, potassium, congestion, comorbidities, and affordability. SGLT2 inhibitors reduce heart failure events across the ejection-fraction spectrum, with or without diabetes. Diuretics relieve congestion but do not replace disease-modifying therapy; modest creatinine increases or low blood pressure should prompt reassessment before treatment withdrawal.
AAVBC's Heart Failure Medication Treatment Utilization Quick Reference Guide equips PCPs and care teams with an evidence-aligned reference for rapid four-pillar HFrEF therapy, appropriate early SGLT2 inhibitor use in HFmrEF and HFpEF, titration and monitoring, avoidance of medications that worsen heart failure, and continuation of therapy when ejection fraction improves. It also provides cost-smart prescribing strategies, generic and formulary alternatives, and closed-loop post-discharge pathways that verify access, labs, fills, and early follow-up. By integrating tolerability, affordability, and continuity of care, the guide helps sustain guideline-directed therapy and improve outcomes for older adults.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of heart failure medication treatment — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of anticoagulation therapies, and provide care teams with the necessary strategies to thrive within a value-based framework.
